There is still need for more preclinical and clinical studies to address which of the hypoxia modifying compounds could boost the anti‐tumour immunity without suppressing it to achieve optimal therapeutic results when combined with PD‐1/PD‐L1 blockade and radiotherapy. Here, CD274 is linked to neoplasm.